198 related articles for article (PubMed ID: 24122978)
1. Overcoming platinum drug resistance with copper-lowering agents.
Chen HH; Kuo MT
Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy.
Kuo MT; Huang YF; Chou CY; Chen HHW
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201235
[TBL] [Abstract][Full Text] [Related]
4. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
5. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
Kuo MT; Fu S; Savaraj N; Chen HH
Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
[TBL] [Abstract][Full Text] [Related]
6. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.
Chen HH; Chen WC; Liang ZD; Tsai WB; Long Y; Aiba I; Fu S; Broaddus R; Liu J; Feun LG; Savaraj N; Kuo MT
Expert Opin Ther Targets; 2015; 19(10):1307-17. PubMed ID: 26004625
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.
Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT
J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751
[TBL] [Abstract][Full Text] [Related]
8. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
9. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
10. Effects of Cu(II) and cisplatin on the stability of Specific protein 1 (Sp1)-DNA binding: Insights into the regulation of copper homeostasis and platinum drug transport.
Yan D; Aiba I; Chen HH; Kuo MT
J Inorg Biochem; 2016 Aug; 161():37-9. PubMed ID: 27172866
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin.
Liang ZD; Stockton D; Savaraj N; Tien Kuo M
Mol Pharmacol; 2009 Oct; 76(4):843-53. PubMed ID: 19570948
[TBL] [Abstract][Full Text] [Related]
12. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1.
Chen HH; Song IS; Hossain A; Choi MK; Yamane Y; Liang ZD; Lu J; Wu LY; Siddik ZH; Klomp LW; Savaraj N; Kuo MT
Mol Pharmacol; 2008 Sep; 74(3):697-704. PubMed ID: 18523133
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters.
Guo Y; Smith K; Petris MJ
J Biol Chem; 2004 Nov; 279(45):46393-9. PubMed ID: 15326162
[TBL] [Abstract][Full Text] [Related]
14. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2010 Sep; 78(3):333-9. PubMed ID: 20519567
[TBL] [Abstract][Full Text] [Related]
15. Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression.
Liang ZD; Tsai WB; Lee MY; Savaraj N; Kuo MT
Mol Pharmacol; 2012 Mar; 81(3):455-64. PubMed ID: 22172574
[TBL] [Abstract][Full Text] [Related]
16. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Jandial DD; Blair BG; Safaei R; Howell SB
Biochem Pharmacol; 2010 Aug; 80(4):448-54. PubMed ID: 20451502
[TBL] [Abstract][Full Text] [Related]
17. Overcoming platinum resistance through the use of a copper-lowering agent.
Fu S; Naing A; Fu C; Kuo MT; Kurzrock R
Mol Cancer Ther; 2012 Jun; 11(6):1221-5. PubMed ID: 22491798
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
19. Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Oncotarget; 2016 Aug; 7(31):49310-49321. PubMed ID: 27384479
[TBL] [Abstract][Full Text] [Related]
20. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
